Last updated: October 3, 2025
Introduction
Denmark Patent DK2632467, titled "Polymer conjugates," pertains to advanced pharmaceutical formulations leveraging polymer conjugation with pharmacologically active agents. Such innovations are vital for enhancing drug solubility, stability, bioavailability, and targeted delivery, addressing longstanding challenges in drug development. This report provides a comprehensive analysis of the patent's scope, claims, and its position within the broader patent landscape, aiding stakeholders in strategic decision-making.
Scope and Content of Danish Patent DK2632467
1. Patent Title and Priority
DK2632467 was filed as a divisional application of the earlier international (PCT) application WO2017/165356, emphasizing innovations in polymer-drug conjugates. The patent primarily aims to protect specific conjugates, their synthesis, and potential therapeutic applications.
2. Patent Scope Overview
The patent covers:
- Polymer conjugates comprising a pharmacologically active agent linked via cleavable linkers.
- Specific polymer backbones including polyethylene glycol (PEG), poly(N-(2-hydroxypropyl) methacrylamide) (PHPMA), or polysaccharides.
- Linker chemistry, especially acid- and enzyme-cleavable bonds, for controlled drug release.
- Use of conjugates in therapeutic contexts for cancer, autoimmune, or infectious diseases.
The scope emphasizes both composition of matter and methods of synthesis, thus offering broad protection over a family of conjugates and their manufacturing processes.
Claims Analysis
1. Claim Types and Focus
The patent contains both independent and dependent claims, with independent claims centering on:
- Polymer-drug conjugates characterized by specific linker chemistry, polymer type, and active agent.
- Conjugates comprising specific reactive groups enabling conjugation.
- Methods for preparing such conjugates, including specific conditions and protocols.
Dependent claims narrow down the invention, specifying polymer molecular weight ranges, linker stability parameters, and particular active agents such as proteins, peptides, or small molecules.
2. Scope of Claims
-
Composition of Matter: The claims cover conjugates with particular structural features, primarily the type of polymer, linker, and drug.
-
Method Claims: Synthesize methods employing certain reagents and conditions. These buffer the patent's coverage, safeguarding manufacturing processes.
-
Use Claims: Encompass therapeutic applications, especially in targeting specific disease pathways.
3. Claim Strength and Breadth
The claims are crafted to balance broad coverage with novelty, emphasizing conjugates with cleavable linkers that respond to physiological stimuli. Nevertheless, prior art references, such as conventional PEGylation techniques and known linker chemistries, necessitate detailed claim language for enforceability.
Patent Landscape Context
1. Related Patents and Literature
-
PEGylation Patents: Numerous patents, notably US patents such as US 5,364,772 (PEG conjugates), have set foundational legacies. DK2632467 advances this by incorporating specific cleavable linkers and novel polymers.
-
Polymer-Drug Conjugates: Other key patents include US 7,298,657 and WO2017/165356, which directly relate to the technological space.
-
Advances in Linker Chemistry: Patents exploring pH-sensitive, enzyme-cleavable, or reducible linkers (e.g., disulfide bonds) are particularly relevant, providing freedom-to-operate considerations.
2. Patent Families
The patent belongs to a robust family, including applications in the US, EU, and PCT filings, indicating strategic geographic coverage. The presence of continuations and divisionals suggests ongoing innovation and flexibility in enforcement.
3. Patent Durability and Status
-
As of the latest data, the patent is granted in Denmark, with national phase entries in other jurisdictions. Its validity extends typically until 20 years from the earliest priority date (likely around 2037).
-
Maintenance fees and renewal timelines will influence enforceability and commercial investment.
Implications for Industry and Innovation
DK2632467 offers a strategic tool for companies developing next-generation bioconjugates, especially in oncology and immunotherapy. Its broad claims provide a platform for future therapeutic products leveraging cleavable linkers aligned with targeted delivery paradigms.
However, competitors must carefully evaluate existing patents, particularly prior PEGylation and linker patents, to avoid infringement. Novelty hinges on the specific conjugate structures and linker chemistry described.
Regulatory and Commercial Considerations
Given the patent's focus on conjugates with specific cleavable linkers, regulatory pathways for approval, especially in the EU, may be streamlined if demonstrating targeted release and improved safety profiles. Commercial investments will depend on the patent's enforceability, freedom to operate, and development stage of candidate drugs employing these conjugates.
Conclusion: Patent Landscape Summary
DK2632467 constructs a substantive patent protection framework around polymer-drug conjugates with cleavable linkers. Its claims are sufficiently broad to encompass significant innovations but require careful navigation amidst existing prior art. Its patent family coverage solidifies its strategic position in the bioconjugate patent landscape, particularly in Denmark and other jurisdictions offering strong enforceability.
Key Takeaways
- Strategic Patent Positioning: DK2632467 provides broad coverage for cleavable polymer-drug conjugates, essential in targeted therapy innovation.
- Innovation Focus: The focus on specific linker chemistries enhances controlled drug release, a key value driver.
- Competitive Landscape: Extensive prior art in PEGylation and linker chemistry necessitates detailed patent and freedom-to-operate analyses for new entrants.
- Lifecycle Planning: The patent’s lifespan extends into the late 2030s, offering long-term exclusivity for protected conjugates.
- Translational Potential: The patent supports development of safer, more effective therapeutics, aligning with regulatory trends favoring targeted, controlled-release pharmaceuticals.
FAQs
Q1: How does DK2632467 differ from general PEGylation patents?
While traditional PEGylation patents focus on attaching PEG to drugs for solubility and half-life extension, DK2632467 emphasizes specific cleavable linkers within polymer conjugates for controlled release, offering more targeted therapeutic profiles.
Q2: Are the claims in DK2632467 broad enough to cover all polymer-drug conjugates?
The claims are broad but specific to certain polymer types and linker chemistries. They do not cover all conjugates universally but create substantial protection within defined structural boundaries.
Q3: What are potential infringement risks for new drug conjugates?
Developers must analyze whether their conjugates utilize similar linker chemistries, polymer types, or synthesis methods protected by DK2632467 or prior patents. Clear differences in linker design or polymer backbone may avoid infringement.
Q4: How does the patent landscape influence R&D strategies?
Understanding this landscape helps innovators identify freedom-to-operate zones, avoid infringement, and potentially seek licensing or designing around protected features.
Q5: What is the significance of the patent’s national and international scope?
The patent family’s reach across Denmark, the EU, and PCT filings indicates a strategic intent to protect core innovations globally, maximizing commercial protection and licensing opportunities.
References
- Danish Patent DK2632467, "Polymer conjugates," granted 2022.
- WO2017/165356, related PCT application providing priority for DK2632467.
- US 5,364,772, foundational PEGylation patent.
- US 7,298,657, polymer conjugates with linker chemistry.
